<DOC>
	<DOCNO>NCT01635127</DOCNO>
	<brief_summary>Evaluation whether canakinumab lead improvement urticaria</brief_summary>
	<brief_title>Efficacy Study Canakinumab Treat Urticaria</brief_title>
	<detailed_description>Single center prospective placebo-controlled cross-over phase II study . - To assess canakinumab induce clinical improvement and/or complete clinical remission chronic idiopathic urticaria week 4 compare placebo - To compare canakinumab placebo treat patient percentage achieve complete clinical remission week 1 , 2 , 4 , 8 . - To compare percentage clinical improvement measure UAS7 score week 1 , 2 , 4 , 8 canakinumab placebo treat patient - To compare percentage canakinumab placebo treat patient 75 % 100 % improvement baseline ( Run-in-period ) UAS7 score week 1,2,4 , 8 - To compare daily wheal score Days 1 7 canakinumab placebo treat patient</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Diagnosis chronic idiopathic urticaria 6 week confirm clinical , necessary , histological examination CIU moderate severe severity define follow Physician severity score 2 3 ( scale 0 3 ) Runin period diarybased UAS7 score &gt; 21 ( scale 0 42 ) Symptomatic despite use nonsedating antihistamine without concomitant leukotriene antagonist/corticosteroids Use maintenance nonsedating antihistamine stable dose least 1 week prior enter runin period Maintenance corticosteroid dose &lt; 20 mg/day &lt; 0.4 mg/kg stable least week prior study entry treatment patient 's CIU allow . Age : &gt; 18 year . Signed informed consent Negative unreactive QuantiFERON test ( QFTTB G InTube ) history adequate treatment active latent tuberculosis . Exclusion criterion : Age &lt; 18 &gt; 70 year History cancer except treat basal cell carcinoma skin With active recurrent bacterial , fungal viral infection time enrollment , include patient evidence Human Immunodeficiency Virus ( HIV ) infection , Hepatitis B Hepatitis C infection , active untreated latent tuberculosis . Patients currently treat systemic immunosuppressive agent follow treatment specified period baseline visit : corticosteroid =20 mg/day &gt; 0.4 mg/kg 1 week prior study entry ; leukotriene antagonist 1 week prior study entry colchicine , dapsone mycophenolate mofetil 3 week ; etanercept , leflunomide ( documentation completion full cholestyramine elimination treatment recent leflunomide use require ) , thalidomide ciclosporin 4 week ; adalimumab intravenous immunoglobulin 8 week ; infliximab , 6mercaptopurine , azathioprine , cyclophosphamide chlorambucil 12 week Live vaccination within 3 month prior start trial , trial , 3 month follow last dose Contraindications class drug study , e.g . know hypersensitivity allergy class drug investigational product , Pregnant lactate woman , patient ( men woman ) plan pregnancy duration study , lack safe contraception . Safe contraception define follow : Doublebarrier contraception oral , injectable , implantable contraceptive , intrauterine contraceptive device together condom use . Both men woman must use safe contraception ( doublebarrier define ) duration study 6 month study . Please note female subject surgically sterilized/hysterectomized postmenopausal longer 2 year consider child bear potential . Inability follow procedure study , e.g . due language problem , psychological disorder , dementia , etc . subject . Participation another study investigational drug within 30 day precede present study . Previous enrolment current study . Enrolment investigator , his/her family member , employee dependent person .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>